AR116115A1 - Dimetil amino azetidina amidas como inhibidores de jak - Google Patents

Dimetil amino azetidina amidas como inhibidores de jak

Info

Publication number
AR116115A1
AR116115A1 ARP190102520A ARP190102520A AR116115A1 AR 116115 A1 AR116115 A1 AR 116115A1 AR P190102520 A ARP190102520 A AR P190102520A AR P190102520 A ARP190102520 A AR P190102520A AR 116115 A1 AR116115 A1 AR 116115A1
Authority
AR
Argentina
Prior art keywords
dimethyl amino
jak inhibitors
compounds
amino azetidine
amides
Prior art date
Application number
ARP190102520A
Other languages
English (en)
Spanish (es)
Inventor
Corbin Thompson
Cameron Smith
Daniel D Long
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of AR116115A1 publication Critical patent/AR116115A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP190102520A 2018-09-04 2019-09-03 Dimetil amino azetidina amidas como inhibidores de jak AR116115A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862726562P 2018-09-04 2018-09-04

Publications (1)

Publication Number Publication Date
AR116115A1 true AR116115A1 (es) 2021-03-31

Family

ID=67982186

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102520A AR116115A1 (es) 2018-09-04 2019-09-03 Dimetil amino azetidina amidas como inhibidores de jak

Country Status (27)

Country Link
US (4) US10947229B2 (https=)
EP (1) EP3837258B1 (https=)
JP (2) JP7324836B2 (https=)
KR (1) KR102826491B1 (https=)
CN (1) CN112739697B (https=)
AR (1) AR116115A1 (https=)
AU (1) AU2019336167B2 (https=)
BR (1) BR112021004052A2 (https=)
CL (1) CL2021000514A1 (https=)
CO (1) CO2021002977A2 (https=)
DK (1) DK3837258T3 (https=)
EA (1) EA202190681A1 (https=)
ES (1) ES2982858T3 (https=)
FI (1) FI3837258T3 (https=)
HR (1) HRP20241002T1 (https=)
HU (1) HUE068058T2 (https=)
IL (1) IL281146B2 (https=)
LT (1) LT3837258T (https=)
MA (1) MA53229A (https=)
MX (1) MX2021002521A (https=)
PH (1) PH12021550368A1 (https=)
PL (1) PL3837258T3 (https=)
PT (1) PT3837258T (https=)
SG (1) SG11202101734RA (https=)
SI (1) SI3837258T1 (https=)
TW (1) TWI791886B (https=)
WO (1) WO2020051105A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA123633C2 (uk) 2015-11-03 2021-05-05 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі Сполуки інгібітору jak-кінази для лікування респіраторного захворювання
WO2018165392A1 (en) 2017-03-09 2018-09-13 Theravance Biopharma R&D Ip, Llc Jak inhibitors containing a 4-membered heterocyclic amide
JP2021535176A (ja) 2018-09-04 2021-12-16 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jak阻害剤およびその中間体を調製するためのプロセス
FI3837258T3 (fi) * 2018-09-04 2024-05-27 Theravance Biopharma R&D Ip Llc Dimetyyliaminoatsetidiiniamideja jak-estäjinä
UA127328C2 (uk) 2018-09-04 2023-07-19 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі 5-7-членні гетероциклічні аміди як інгібітори jak
TW202144343A (zh) * 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
CN115803023A (zh) * 2020-05-08 2023-03-14 施万生物制药研发Ip有限责任公司 发用奈珠西替尼治疗感染冠状病毒的患者的方法
WO2022271604A1 (en) 2021-06-21 2022-12-29 Theravance Biopharma R&D Ip, Llc Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l
EP4359402B1 (en) * 2021-06-25 2026-03-11 Theravance Biopharma R&D IP, LLC Imidazolo indazole compounds as jak inhibitors
KR20230092805A (ko) * 2021-12-17 2023-06-26 주식회사 대웅제약 (2R, 3S)-2-(3-(4,5-디클로로-1H-벤조[d]이미다졸-1-일)프로필)피페리딘-3-올의 신규한 산부가염 및 결정형
US20250288561A1 (en) 2022-05-05 2025-09-18 Theravance Biopharma R&D Ip, Llc Nezulcitinib for delivery by nebulized oral inhalation
WO2023230236A1 (en) 2022-05-26 2023-11-30 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
EP1648455A4 (en) 2003-07-23 2009-03-04 Exelixis Inc MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ttk阻害作用を有するインダゾール誘導体
WO2010114971A1 (en) 2009-04-03 2010-10-07 Sepracor Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
LT3001903T (lt) 2009-12-21 2018-01-10 Samumed, Llc 1h-pirazolo[3,4-b]piridinai ir jų terapinis panaudojimas
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
SI3077395T1 (en) 2013-12-05 2018-03-30 Pfizer Inc. Pyrrolo(2,3-d)pyrimidinyl, pyrrolo(2,3-b)pyrazinyl and pyrrolo(2,3-d)pyridinyl acrylamides
KR20170002623A (ko) 2014-05-14 2017-01-06 화이자 인코포레이티드 피라졸로피리딘 및 피라졸로피리미딘
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
DK3371185T3 (da) 2015-11-03 2020-11-30 Topivert Pharma Ltd 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus-kinase-inhibitorer
WO2017077283A1 (en) 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
UA123633C2 (uk) * 2015-11-03 2021-05-05 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі Сполуки інгібітору jak-кінази для лікування респіраторного захворювання
WO2018165392A1 (en) 2017-03-09 2018-09-13 Theravance Biopharma R&D Ip, Llc Jak inhibitors containing a 4-membered heterocyclic amide
US20180258546A1 (en) 2017-03-09 2018-09-13 Lam Research Corporation Electroplating apparatus and methods utilizing independent control of impinging electrolyte
KR20200003121A (ko) 2017-05-01 2020-01-08 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 저해제 화합물의 결정형
WO2018204233A1 (en) 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Methods of treatment using a jak inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CN112566713A (zh) 2018-07-20 2021-03-26 波里费拉公司 具有再循环回路的渗透模块
UA127328C2 (uk) 2018-09-04 2023-07-19 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі 5-7-членні гетероциклічні аміди як інгібітори jak
FI3837258T3 (fi) 2018-09-04 2024-05-27 Theravance Biopharma R&D Ip Llc Dimetyyliaminoatsetidiiniamideja jak-estäjinä
JP2021535176A (ja) 2018-09-04 2021-12-16 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jak阻害剤およびその中間体を調製するためのプロセス
KR20210084512A (ko) 2018-10-29 2021-07-07 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제로서 2-아자비시클로 헥산 화합물
HUE067145T2 (hu) 2019-02-25 2024-10-28 Henan Medinno Pharmaceutical Tech Co Ltd JAK inhibitor vegyület és alkalmazása
WO2020181034A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
CN112279848A (zh) 2019-07-25 2021-01-29 四川海思科制药有限公司 一种泛JAKs抑制剂及其用途
TW202144343A (zh) * 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
CN115803023A (zh) 2020-05-08 2023-03-14 施万生物制药研发Ip有限责任公司 发用奈珠西替尼治疗感染冠状病毒的患者的方法
WO2022178215A1 (en) 2021-02-19 2022-08-25 Theravance Biopharma R&D Ip, Llc Amino amide tetrahydro imidazo pyridines as jak inhibitors
WO2022204473A1 (en) 2021-03-26 2022-09-29 Theravance Biopharma R&D Ip, Llc Crystalline form of a dihydrochloride salt of a jak inhibitor compound
WO2022271604A1 (en) * 2021-06-21 2022-12-29 Theravance Biopharma R&D Ip, Llc Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l

Also Published As

Publication number Publication date
SI3837258T1 (sl) 2024-09-30
US20210155620A1 (en) 2021-05-27
US11634419B2 (en) 2023-04-25
LT3837258T (lt) 2024-05-27
EP3837258B1 (en) 2024-04-24
TWI791886B (zh) 2023-02-11
EA202190681A1 (ru) 2021-05-28
DK3837258T3 (da) 2024-07-22
PT3837258T (pt) 2024-06-20
IL281146B2 (en) 2023-12-01
IL281146B1 (en) 2023-08-01
IL281146A (en) 2021-04-29
US10947229B2 (en) 2021-03-16
MA53229A (fr) 2022-05-11
PL3837258T3 (pl) 2024-09-16
CL2021000514A1 (es) 2021-07-23
CO2021002977A2 (es) 2021-05-31
HUE068058T2 (hu) 2024-12-28
JP7324836B2 (ja) 2023-08-10
BR112021004052A2 (pt) 2021-05-25
CN112739697B (zh) 2023-10-20
TW202024073A (zh) 2020-07-01
JP2022172299A (ja) 2022-11-15
EP3837258A1 (en) 2021-06-23
KR20210056381A (ko) 2021-05-18
PH12021550368A1 (en) 2022-03-28
MX2021002521A (es) 2021-04-28
AU2019336167A1 (en) 2021-03-11
JP2021535177A (ja) 2021-12-16
US20230322774A1 (en) 2023-10-12
SG11202101734RA (en) 2021-03-30
US20200071323A1 (en) 2020-03-05
HRP20241002T1 (hr) 2024-10-25
US20250034131A1 (en) 2025-01-30
KR102826491B1 (ko) 2025-06-27
US12398135B2 (en) 2025-08-26
AU2019336167B2 (en) 2024-08-29
WO2020051105A1 (en) 2020-03-12
ES2982858T3 (es) 2024-10-17
FI3837258T3 (fi) 2024-05-27
CN112739697A (zh) 2021-04-30

Similar Documents

Publication Publication Date Title
AR116115A1 (es) Dimetil amino azetidina amidas como inhibidores de jak
MX2019010539A (es) Compuestos de imidazo-piperidina fusionada que contienen una amida heterociclica de 4 miembros como inhibidores de jak.
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
CO2019011809A2 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CY1121062T1 (el) Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου alzheimer
CO2017004481A2 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
CO2017000399A2 (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
CO2021002976A2 (es) Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
EA201990902A1 (ru) Ингибиторы тирозинкиназы брутона
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
AR113803A1 (es) Compuesto de pirimidina como inhibidor de jak quinasas
CU20170007A7 (es) Compuestos de imidazopiridazina
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
MX2018010177A (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida.
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
EA201990109A1 (ru) Митохондриальные ингибиторы для лечения пролиферативных нарушений
AR098319A1 (es) Profármacos de antagonista de nmda
CY1122375T1 (el) Συμπυκνωμενα με τετραϋδροφουρανιο αμινοϋδροθειαζινικα αναλογα τα οποια ειναι χρησιμα στη θεραπεια της νοσου toy alzheimer
AR105921A1 (es) Compuestos terapéuticos para el dolor y síntesis de estos
AR113794A1 (es) Inhibidores de trpc6
EA201892640A1 (ru) Лечение болезни паркинсона

Legal Events

Date Code Title Description
FA Abandonment or withdrawal